• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature reviews. Urology >The role of ketoconazole in current prostate cancer care
【24h】

The role of ketoconazole in current prostate cancer care

机译：酮康唑在目前前列腺癌护理中的作用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Ketoconazole is a nonselective steroid 17 alpha-hydroxylase/17,20 lyase (CYP17A1) inhibitor that has been used, off-label, as a second-line therapy for castration-resistant prostate cancer (CRPC). The drug has shown clinical efficacy without survival benefit. Despite not improving survival, ketoconazole has beneficial characteristics, such as its low cost, a relatively favourable toxicity profile compared with chemotherapy, and its efficacy both before and after chemotherapy. The approval of several new, highly effective treatments, including abiraterone acetate, enzalutamide, and apalutamide, warrants re-evaluation of the role of ketoconazole and other classic agents in achieving the optimal timing and sequencing of available agents to prolong survival and maintain patients' quality of life. In the current CRPC treatment landscape, we believe that ketoconazole can be considered in patients with nonmetastatic CRPC and in those with metastatic CRPC who do not respond to, tolerate, or have access to chemotherapy and other standard therapeutic options.
机译：酮康唑是一种非选择性类固醇17α-羟化酶/ 17,20次裂解酶（CYP17A1）抑制剂，其被使用，作为抗阉割前列腺癌（CRPC）的二线疗法。该药物已显示临床疗效而不存在生存益处。尽管生存没有改善，酮康唑具有有益的特点，例如其低成本，与化疗相比，相对有利的毒性曲线，以及化疗之前和之后的疗效。批准几种新的高效治疗，包括Abiraatorone醋酸盐，依甲醛胺和奥氟胺酰胺，可根据酮康唑和其他经典药物的作用进行重新评估，以实现可用药剂的最佳时间和测序以延长生存和维持患者的质量生活。在目前的CRPC治疗景观中，我们认为酮康唑可以考虑非更换CRPC的患者，并且在没有响应，耐受或可以获得化疗和其他标准治疗选择的转移性CRPC的患者中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号